Link Andreas, Ayadhi Tarek, Böhm Michael, Nickenig Georg
Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, D-66421Homburg/Saar, Germany.
Eur Heart J. 2006 Dec;27(24):2945-55. doi: 10.1093/eurheartj/ehl277. Epub 2006 Sep 29.
HMG-CoA reductase inhibitors (statins) reduce cardiovascular mortality and morbidity in patients with stable coronary artery disease as well as acute coronary syndrome (ACS). It is unclear how rapidly the beneficial effects of statins occur in patients with ACS and whether these drug properties are related to lipid lowering.
Patients with troponin-positive ACS (n=35) were randomized to 20 mg/day rosuvastatin therapy or to placebo treatment. Anti-inflammatory effects of rosuvastatin measured by lymphocyte intracellular cytokine production were taken before initiation of treatment and on days 1, 3, and 42. Compared with placebo, rosuvastatin treatment significantly reduced plasma concentrations of pro-inflammatory cytokines TNF-alpha and IFN-gamma at 72 h. Rosuvastatin also induced a rapid and significant reduction of TNF-alpha and IFN-gamma production in stimulated T-lymphocytes at 72 h. When compared with placebo, rosuvastatin inhibited the Th-1-immune response measured at 72 h.
Rosuvastatin exerts rapid immunomodulatory effects on the level of T-cell activation in patients with ACS.
HMG-CoA还原酶抑制剂（他汀类药物）可降低稳定型冠状动脉疾病以及急性冠状动脉综合征（ACS）患者的心血管死亡率和发病率。目前尚不清楚他汀类药物对ACS患者的有益作用出现得有多快，以及这些药物特性是否与降脂有关。
肌钙蛋白阳性的ACS患者（n = 35）被随机分为接受20毫克/天瑞舒伐他汀治疗或安慰剂治疗。在治疗开始前以及第1、3和42天，通过淋巴细胞细胞内细胞因子产生情况来测定瑞舒伐他汀的抗炎作用。与安慰剂相比，瑞舒伐他汀治疗在72小时时显著降低了促炎细胞因子TNF-α和IFN-γ的血浆浓度。瑞舒伐他汀还在72小时时使受刺激的T淋巴细胞中TNF-α和IFN-γ的产生迅速且显著减少。与安慰剂相比，瑞舒伐他汀在72小时时抑制了Th-1免疫反应。
瑞舒伐他汀对ACS患者的T细胞活化水平具有快速的免疫调节作用。
